A study comparing two dosing methods of Sugammadex for recovery of Muscle relaxation during Minor Gynecological Laparoscopic Procedure

Comparison of effect of Sugammadex 2mg/kg and Fixed Dose 100mg for Vecuronium Induced Shallow Neuromuscular Block in Patients undergoing Diagnostic Hysterolaparoscopy. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102442

Enrollment

Registered

2026-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sugammadex 2mg per kg: Sugammadex 2mg per kg will be administered for reversal of vecuronium induced shallow neuromuscular block in patients undergoing diagnostic hysterolaparoscopy aft

Eligibility

Inclusion criteria

Inclusion criteria: 1.BMI-18-25 2.ASA 1,2 and 3 3.Patients willing to participate in the study 4.Duration of surgery under Gerneral anesthesia less than 2hrs 5.Preoperative spo2-98-100 percent on Room air

Exclusion criteria

Exclusion criteria: 1.Lack of valid informed written consent 2.ASA GRADE 4 3.BMImore than 25 4.Patients with bleeding disorders 5.Patients on anticoagulants 6.Allergies to food and drugs 7.Patients with cardiac,renal,hepatic and respiratory co-morbidities

Design outcomes

Primary

Measure	Time frame
It is expected that Sugammadex at the recommended dose of 2mg/kg will result in a faster and complete reversal(TOF-0.9) of vecuronium-induced neuromuscular blockade , compared to a fixed dose of 100mg, with no instances of residual blockade, comparable safety profiles and adverse events.Timepoint: Assessment will be done at 2 hours.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Sanjot Ninave

Datta Meghe Institute of Higher Education and Research

drsusann02@rediffmail.com9921213404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026